Article info

Download PDFPDF

Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phase IV randomised controlled trial (PRIME-V study)

Authors

  1. Correspondence to Professor Koutaro Yokote; kyokote{at}faculty.chiba-u.jp
View Full Text

Citation

Koshizaka M, Ishikawa K, Ishikawa T on behalf of the PRIME-V Study Investigators, et al
Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phase IV randomised controlled trial (PRIME-V study)

Publication history

  • Received January 6, 2017
  • Revised March 7, 2017
  • Accepted March 17, 2017
  • First published May 9, 2017.
Online issue publication 
May 09, 2017

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.